Trial results for a study evaluating tofacitinib in patients with Psoriatic Arthritis were posted on ClinicalTrials.gov on 2025-10-14, showing up to 47.4% of participants achieved low disease activity at 12 months.
Background
Psoriatic Arthritis is a chronic inflammatory disease that affects the joints and often occurs in people with psoriasis. Managing the condition involves reducing joint inflammation, preventing joint damage, and improving physical function and quality of life. Evaluating treatments like tofacitinib in routine clinical practice provides valuable real-world data on their effectiveness in managing disease activity and achieving remission.
Trial design
This completed multinational study enrolled 116 participants diagnosed with Psoriatic Arthritis. The trial aimed to evaluate the effectiveness of treatment with tofacitinib on disease activity, remission, and Quality of Life in a real-world setting over a 12-month observation period.
Key results
The study reported several key measurements regarding disease activity:
- Percentage of Participants Who Achieved Low Disease Activity (LDA) Based on Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 6:
- 43.1% of participants achieved LDA.
- 46.9% of participants achieved LDA.
- 33.4% of participants achieved LDA.
- 4.0% of participants achieved LDA.
- Percentage of Participants Who Achieved LDA Based on PASDAS at Months 3 and 12:
- At Month 3, 23.5% of participants achieved LDA.
- At Month 3, 21.1% of participants achieved LDA.
- At Month 3, 33.3% of participants achieved LDA.
- At Month 3, 0% of participants achieved LDA.
- At Month 12, 46.2% of participants achieved LDA.
- At Month 12, 47.4% of participants achieved LDA.
- At Month 12, 42.9% of participants achieved LDA.
- Percentage of Participants Who Achieved Minimum Disease Activity (MDA) at Months 3, 6 and 12:
- 17.6% of participants achieved MDA.
What this means
The posted results offer insights into the real-world effectiveness of tofacitinib for patients with Psoriatic Arthritis. The varying percentages of participants achieving low disease activity and minimum disease activity at different time points (Months 3, 6, and 12) provide clinicians with practical data on patient responses in routine clinical settings. These findings contribute to the understanding of how tofacitinib may help manage disease activity and improve outcomes for individuals living with Psoriatic Arthritis.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04517669, titled "Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice", were posted on 2025-10-14 on clinicaltrials.gov.